Atossa Genetics Stock News

PARIS : France''s Atos aims to double its global market share in supercomputing to about 16per cent by around 2026, one of its executive said, stepping up European competition in a field dominated by the United States and China. The technology and IT consulting firm presented on Wednesday a new generation

The Group structures its activities around three distinct Business Lines and four Regions

German shares boosted by Siemens; Atos drags down European tech stocks Financial Post

PARIS (Reuters) French IT consulting firm Atos said late on Wednesday that it took total writedowns of 2.4 billion euros ($2.74 billion) in the second-half of 2021 as part of a reshuffling of the group around three core activities.

IceCure Medical ICCM +16%. Atossa Therapeutics (ATOS) +15%. Dermata Therapeutics (DRMA) -31%. Statera Biopharma STAB -26%.

By Mathieu Rosemain and Julien Ponthus PARIS (Reuters) The French government holds the final keys to any move to buy the BDS cybersecurity division of Frances Atos, industry sources and analysts said, after French defence company Thales was reported to be devising a break-up plan.

Atos shareholders may be the winners from a possible deal involving Thales and private equity. The 3.7 billion euro IT company, which has halved in value over the past year after an accounting snafu, could be broken up, Reuters reported . Defence group Thales would pick up the cybersecurity business for $3 billion (2.7 billion euros), with buyout funds like Bain Capital taking the rest.

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet

Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease Nebulized Formulation Being D

Futures Resume Tumbling After Yields Spike To New 2 Year High The new week has picked up where last week left off: with futures selling off and global markets lower as yields continued their relentless treck higher, hitting fresh two year highs (amid concerns of a faster Fed balance sheet drawdown coupled with a massive IG issuance slate forcing managers to put on rate locks in what remains an illiquid market). US index futures traded down to session lows as US traders sat at their desks after rising modestly earlier in the session, and were down 27 points or 0.6% at 730am ... while Treasury yields stabilized after reversing an earlier spike rising as high as 1.8064% before dropping to 1.7656% following a global bond selloff last week as investors awaited key inflation data later in the week. Tech stocks again led the decline with Nasdaq futs down 0.63%, while Dow futures were down 0.12% or 44 points. The dollar rose, bitcoin dropped and crude oil steadied around $79 a barrel. Market volatility continues to grow almost everywhere, with lingering uncertainties keeping pressure on sentiment, said Pierre Veyret, technical analyst at ActivTrades. Traders are likely to wait for new major market drivers before pushing stock prices in new directions.

Parametric Portfolio Associates LLC acquired a new position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) during the second quarter, Holdings Channel reports. The institutional investor acquired 52,128 shares of the companys stock, valued at approximately $329,000. Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cubist Systematic []

SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet m

SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast density, which is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide.